Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

NCT00629551
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
saredutant (SR48968), paroxetine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

NCT01010204
View directory record Official record
Conditions
Smoking Cessation, Bipolar Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
DuBois, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

A Study in Patients With Trichotillomania

NCT03797521
View directory record Official record
Conditions
Trichotillomania
Interventions
SXC-2023, Placebo
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Pico Rivera, California • Riverside, California • North Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 26, 2026, 4:39 AM EDT
Not listed Phase 1Phase 2 Interventional

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

NCT04669587
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
ZB716, Palbociclib
Drug
Lead sponsor
EnhancedBio USA Inc.
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pomegranate Extract and Memory

NCT01950221
View directory record Official record
Conditions
Healthy Volunteers
Interventions
POMx, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)

NCT00453921
View directory record Official record
Conditions
Brain Injury
Interventions
Methylphenidate, Memory and Attention Training, Placebo as both treatments
Drug · Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Denver, Colorado • Indianapolis, Indiana • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

NCT01543685
View directory record Official record
Conditions
Other Acute Postoperative Pain
Interventions
Indomethacin, Celecoxib, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

NCT02685709
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

NCT00613938
View directory record Official record
Conditions
Arthralgia, Bunion, Hallux Valgus, Pain
Interventions
Tapentadol (CG5503), oxycodone, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

NCT00326716
View directory record Official record
Conditions
HIV Infection
Interventions
Atazanavir + Ritonavir + Combivir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04429555
View directory record Official record
Conditions
Pneumonia, Viral
Interventions
Ibudilast, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

NCT02215252
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 4 Interventional

Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia

NCT00488163
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Brentwood, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

NCT01141504
View directory record Official record
Conditions
Healthy Subjects
Interventions
PeakATP 250, Placebo, PeakATP 400, PeakATP 400 plus proprietary blend
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
20 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

PTSD Prevention Using Oral Hydrocortisone

NCT04924166
View directory record Official record
Conditions
PTSD, Acute Stress Disorder, Trauma-related Stressor
Interventions
Placebo, Hydrocortisone
Drug
Lead sponsor
Rachel Yehuda
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

NCT04674761
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Odevixibat, Placebo
Drug
Lead sponsor
Albireo
Industry
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 26, 2026, 4:39 AM EDT
Active, not recruiting Early Phase 1 Interventional

Fecal Microbiota Transplant for Autobrewery Syndrome

NCT06083142
View directory record Official record
Conditions
Auto-Brewery Syndrome, Gut Fermentation Syndrome
Interventions
Fecal microbiota transplantation capsules
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 26, 2026, 4:39 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Milvexian, Apixaban, Placebo, Apixaban Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
20,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
216
States / cities
Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 4:39 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

NCT01874366
View directory record Official record
Conditions
Overweight, Diabetes Mellitus Type 2 in Obese
Interventions
P11187, Placebo
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
Tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

NCT05184192
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
Interventions
Gabapentin gelatin capsules 300mg, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 26, 2026, 4:39 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

NCT01081912
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Placebo, Hydrocodone bitartrate
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
51
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 26, 2026, 4:39 AM EDT